. . .

Stock Volume under Radar: NantKwest, Inc. (NK)

NantKwest, Inc. (NK)

NantKwest (NK) generated a result change of 2.98% and settled at the share price of $1.73 on close of Tuesday trading session. NK stock observed the trading of 529670 shares, while an average trading volume registered with 179.85K shares. Volume can offer useful information when day trading. If for nothing else, use volume to help isolate stocks you want to day trade. Ideally, your day-trading stocks should have lots of average volume so you can enter and exit easily.

Volume can also be used to analyze the trend of a stock, helping to assess the likelihood that the trend will continue to reverse. Volume analysis isn’t perfect and it offers only supplemental information, so you don’t need to feel pressured to start analyzing volume to day trade successfully.

The stock recorded 11.30% monthly volatility. For the last week, the stock has an average volatility of 13.16%. 1.20% of shares are owned by insiders’ investors and 5.70% shares are owned by institutional investors.

Shares of NantKwest (NK) have been seen trading 41.74% away from the 200-day moving average and 40.13% off the 50-day moving average while 30.14% off the 20-day moving average. One of the widely used tools is the simple moving averages. When the price of the stock rises above the moving average, it’s a buy signal, and when the price falls below the moving average, it is a sell signal. The stock is currently trading -13.07% away from the 52-week high and separated 86.02% from the 52-week low.

ROE is -44.90%. ROE, or net profit divided by equity capital, shows profit earned in comparison with shareholder money. The higher the ratio, the more efficient the company is in using shareholder capital. ROA is at -37.20%. ROA, or net profit by total assets, shows how efficient the management is at using assets to generate earnings.

Presently RSI indicator value is noted at 69.03. RSI compares the magnitude of recent gains to recent losses to see if an asset is oversold or overbought. RSI is plotted on a scale of 0-100. Generally, if it is above 70, the stock is considered overbought and so one can look to sell it. Similarly, an RSI of less than 30 indicates the stock is oversold and can be bought.

NantKwest, Inc. (NK) on December 3, 2019 declared promising safety data generated from the first six patients in its QUILT-3.064 trial. The first-in-human study evaluated the safety and preliminary efficacy of the Company’s first-in-class, tumor-targeted PD-L1.t-haNK cell therapy in patients with locally advanced or metastatic solid tumors.

On December 2, 2019 at the NantKwest Key Opinion Leader and Investors conference, Dr. Soon-Shiong described the clinical development plans for two of NantKwest’s first-in-class NK products: haNK, which was developed to target binding to approved monoclonal therapies such as Trastuzumab, Rituximab and Cetuximab; and PD-L1.t-haNK, which was also designed to target these approved therapies plus directly target PD-L1-expressing tumor cells.

PD-L1.t-haNK cells are a human-derived, allogeneic, natural killer cell line engineered to express a chimeric antigen receptor (CAR) targeting PD-L1, whose origins arise from NantKwest’s proprietary NK-92 (aNK) master cell bank. In addition to targeting PD-L1, PD-L1.t-haNK is engineered to produce intracellular IL-2 for enhanced CD16-targeted antibody-dependent cellular cytotoxicity capabilities.

The QUILT-3.064 study is an open-label, Phase 1 study of PD-L1.t-haNK in subjects with locally advanced or metastatic solid cancers to evaluate safety, preliminary efficacy, determine maximum tolerated dose (MTD) or highest tolerated dose (HTD) and designate the recommended Phase 2 dose (RP2D). The study is being conducted in two parts: the first is evaluating dose escalation using a 3 + 3 design and the second part will evaluate the expansion of the recommended Phase 2 dose (RP2D) to further assess the safety and efficacy of PD-L1.t-haNK therapy. In part one, six subjects were sequentially enrolled, starting at dose level 1 and assessed for dose-limiting toxicities. The primary study objectives are to determine the MTD or HTD, RP2D (recommended phase 2 dose), and safety. The secondary endpoints include objective response rate (ORR), progression free survival (PFS) and overall survival (OS).

Current Ratio of 5.7, describes the coverage current assets of the company provide for the current liabilities. Quick Ratio is listed at 5.7. Quick Ratio (Acid Test): Same as Current Ratio but does not include inventory in the current assets since inventory can be hard to quickly convert to liquid cash when needed. The stock revealed Total Debt/Equity Ratio is 0.01.

P/E is a measure of how the stock is priced in the market relative to the earnings per share. Price to Book Value (P/B) is 1.25: P/B measures how the stock is priced in the market relative to the book value per share. The company expected to grow -1.70% in coming 5 years. Growth rates are very important while analyzing the long term growth and valuation of a certain company. The company estimated this year earnings growth with -119.10% and expected to grow 54.10% in coming one year.

Leave a Reply

Your email address will not be published. Required fields are marked *